pLenti_EF1a_EV
              
              
                (Plasmid
                
                #183116)
              
            
            
            
          - 
            PurposeEmpty vector control for pLenti_EF1a constructs
 - 
              Depositing Lab
 - 
          Sequence Information
 
Ordering
| Item | Catalog # | Description | Quantity | Price (USD) | |
|---|---|---|---|---|---|
| Plasmid | 183116 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $89 | |
Backbone
- 
            Vector backbonepLenti-EF1a-Gate-PGK-hygro
 - Backbone size w/o insert (bp) 10000
 - Total vector size (bp) 10147
 - 
              Vector typeMammalian Expression, Lentiviral
 - 
                Selectable markersHygromycin
 
Growth in Bacteria
- 
            Bacterial Resistance(s)Kanamycin, 50 μg/mL
 - 
            Growth Temperature30°C
 - 
            Growth Strain(s)NEB Stable
 - 
            Copy numberHigh Copy
 
Gene/Insert
- 
                Gene/Insert nameSmall multiple cloning site
 - 
                    SpeciesSynthetic
 - 
                  Insert Size (bp)136
 - Promoter EF1a
 
Cloning Information
- Cloning method Gateway Cloning
 - 5′ sequencing primer 3' EF1a-fwd: CTTCCATTTCAGGTGTCGTG
 - 3′ sequencing primer 3' PGK-rev: CTTTTGAAGCGTGCAGAATG (Common Sequencing Primers)
 
Resource Information
- 
            A portion of this plasmid was derived from a plasmid made byDr. Gang Lu
 
Terms and Licenses
- 
        Academic/Nonprofit Terms
 - 
      Industry Terms
- Not Available to Industry
 
 
Trademarks:
- Zeocin® is an InvivoGen trademark.
 
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
- 
              
For your Materials & Methods section:
pLenti_EF1a_EV was a gift from William Kaelin (Addgene plasmid # 183116 ; http://n2t.net/addgene:183116 ; RRID:Addgene_183116) - 
                
For your References section:
Sensitivity of VHL mutant kidney cancers to HIF2 inhibitors does not require an intact p53 pathway. Stransky LA, Vigeant SM, Huang B, West D, Denize T, Walton E, Signoretti S, Kaelin WG Jr. Proc Natl Acad Sci U S A. 2022 Apr 5;119(14):e2120403119. doi: 10.1073/pnas.2120403119. Epub 2022 Mar 31. 10.1073/pnas.2120403119 PubMed 35357972